| Literature DB >> 34094076 |
Shubham Deolka1, Orestes Rivada-Wheelaghan1, Sandra L Aristizábal1, Robert R Fayzullin2, Shrinwantu Pal3, Kyoko Nozaki3, Eugene Khaskin1, Julia R Khusnutdinova1.
Abstract
We report the selective formation of heterobimetallicEntities:
Year: 2020 PMID: 34094076 PMCID: PMC8159365 DOI: 10.1039/d0sc00646g
Source DB: PubMed Journal: Chem Sci ISSN: 2041-6520 Impact factor: 9.825
Scheme 1Schematic representation of the altering reactivity of a single metal center through heterobimetallic complex formation.
Scheme 2(a) Synthesis of ligand L; (b) selective binding to PtII and PtIV centers via hard and soft sites.
Scheme 3Formation of cationic heterobimetallic complexes 3[X] and a dearomatized heterobimetallic complex 4.
Fig. 1ORTEP of 3[B(ArF)4] (a) and 4 (b) at the 50% probability level. Hydrogen atoms, the counterions for 3[B(ArF)4], and solvent molecules for 4 are omitted for clarity. In the case of 4, only one of three symmetrically independent molecules is shown. Hereinafter coordination bonds are shown in accordance with AIM analysis for the gas-phase optimized structures.
Selected interatomic and bond distances in complexes 3[X] determined by XRD and τ4 values for the Pt center
| Bond distance |
|
|
|
|---|---|---|---|
| Pt1–C1 | 2.201(2) | 2.251(12) | 2.164(3) |
| Pt1–C2 | 2.050(2) | 2.048(11) | 2.048(3) |
| Pt1–N12 | 2.1823(19) | 2.172(9) | 2.1894(19) |
| Pt1–P1 | 2.2280(6) | 2.228(3) | 2.2180(6) |
| Cu1–N11 | 2.064(2) | 2.038(10) | 2.076(2) |
| Cu1–N2 | 2.320(2) | 2.335(11) | 2.322(2) |
| Cu1–N3 | 1.966(2) | 1.982(10) | 1.953(2) |
| Cu1–C1 | 2.277(2) | 2.362(9) | 2.160(3) |
| Pt1–Cu1 | 2.6486(3) | 2.625(2) | 2.6119(3) |
|
| 0.10 | 0.10 | 0.13 |
|
| 0.07 | 0.07 | 0.09 |
Atom numbering is according to Fig. 1a.
Selected interatomic and bond distances in complex 4 determined by XRD and τ4 values for the Pt centera
|
| |||
|---|---|---|---|
| Bond distance |
|
|
|
| Pt–CA | 2.109(5) | 2.127(5) | 2.124(5) |
| Pt–CB | 2.062(5) | 2.050(5) | 2.060(5) |
| Pt–N′ | 2.156(3) | 2.174(4) | 2.171(3) |
| Pt–P | 2.2371(11) | 2.2428(11) | 2.2427(11) |
| Cu–N′′ | 1.933(4) | 1.939(4) | 1.939(4) |
| Cu–Nam | 2.346(4) | 2.317(4) | 2.301(4) |
| Cu–Npy | 1.925(4) | 1.937(4) | 1.941(4) |
| Cu–CA | 2.558(5) | 2.518(5) | 2.559(5) |
| Pt–Cu | 2.6890(5) | 2.7459(6) | 2.7201(5) |
|
| 0.12 | 0.10 | 0.11 |
|
| 0.07 | 0.07 | 0.07 |
For each symmetrically independent molecule.
General scheme for atom labelling in coordination spheres of Pt and Cu is shown above.
From XRD data for the 1st symmetrically independent molecule.
From XRD data for the 2nd symmetrically independent molecule.
From XRD data for the 3rd symmetrically independent molecule.
Diagnostic chemical shifts and coupling constants of complexes 1, 3[X] and 4 in THF-d8
|
| |||||
|---|---|---|---|---|---|
| Complex |
|
|
| ||
| MeA | MeB | MeA | MeB | Pt | |
|
| 0.93 (66) | 0.96 (94) | 15.7 (662) | −21.9 (805) | −3894 (2006) |
|
| 1.10 (44) | 1.23 (86) | −5.9 (491) | −21.3 (711) | −3971 (2877) |
|
| 1.04 (36) | 1.18 (82) | −5.6 (n.d.) | −21.3 (719) | −3971 (2866) |
|
| 0.82 (56) | 0.88 (84) | 3.0 (n.d.) | −20.2 (n.d.) | −3980 (2467) |
Not determined due to low intensity caused by insufficient solubility; the corresponding 1JC,Pt for MeA in CD3CN solution was determined to be 505 Hz (see Table S1).
Not determined due to low intensity caused by insufficient solubility.
Fig. 21H NMR spectra (THF-d8, 25 °C) of isolated complexes 1 (top), 3[B(ArF)4] (middle) and dearomatized complex 4 (bottom). Blue rectangles highlight the naphthyridine-CH2 signal or CH for 4. Green rectangle highlights the naphthyridine Csp–H signals of 4.
Fig. 3Molecular graphs for “gas-phase” DFT-optimized complexes 3+ (a), 4 (b), 6+ (c), and 7+ (d). Bond critical points (3, −1) with a threshold of ∇ρb > 0.025 a.u. and corresponding bond paths are shown with green dots and black lines, respectively.
Scheme 4(a) Cyclometalation of 1; (b) aryl group transfer from the [B(ArF)4]− counterion to give 6; (c) terminal alkyne activation.
Fig. 4ORTEP of 6[B(ArF)4] (a) and 7[BF4] (b) at the 50% probability level. Hydrogen atoms, counterions, and solvent molecules together with the minor disorder component for 7[BF4] are omitted for clarity.
Fig. 5Calculated energy profile for alkyne activation and DFT-optimized structures for intermediates and transition states.